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Novel Drug Treatment for Diabetic Nephropathy
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Diabetic nephropathy (DN) is the leading cause of end-stage renal disease. In addition to the renin pathway, 
certain bioactive molecules are involved in its pathogenesis. Strategies to interrupt pathophysiological pathways 
are on the horizon. Aliskiren, a renin inhibitor, blocks the first step in the renin pathway. Protein kinase C over-
expression is blocked by ruboxistaurin. Pentoxifylline and m-TOR inhibitors are anti-inflammatory agents in 
the pathogenesis of diabetic nephropathy. Inhibitors of advanced glycation, oxidative stress, and plasminogen 
activator inhibitor-1 have proved useful in animal models of diabetic nephropathy. Avosentan, an endothelin 
antagonist, decreases urinary albumin. Such targeted therapies have opened up avenues for researchers to develop 
agents that can halt and may even reverse the progression of diabetic nephropathy. [Hong Kong J Nephrol 
2011;13(1):19–26]
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The burden of diabetes has increased worldwide and is 
expected to affect 380 million persons in 2025 [1,2]. 
Diabetic nephropathy (DN) is the leading cause of end-
stage renal disease (ESRD), and approximately 30% of 
patients with type 1 diabetes (DM1) or type 2 diabetes 
(DM2) develop DN [3]. The phases of clinical progression 
have been described by Mogensen [4]: 1) hyperfiltration 
with renal hypertrophy, increased renal plasma flow, and 
glomerular filtration; 2) normoalbuminuria with early renal 
parenchymal changes (basement membrane thickening 
and mesangial expansion); 3) microalbuminuria with early 
hypertension; 4) overt proteinuria; and 5) ESRD.
Understanding the pathomechanism of DN has helped 
in designing a rational approach for optimal therapy and 
prevention of DN. Hyperglycemia can lead to the activa-
tion of oxidative stress and increased production of reac-
tive oxygen species (ROS). It can also lead to activation 
of the proinflammatory transcription factor NF-κB, 
resulting in increased inflammatory gene expression, 
enhanced flux into the polyol and hexosamine pathways, 
and activation of protein kinase C (PKC), transforming 
growth factor-β (TGF-β), and the renin-angiotensin-
aldosterone system (RAAS). There is also increased forma-
tion of advanced glycation end-products (AGEs). These 
factors collectively result in cell injury and apoptosis of 
podocytes, and the accumulation of extracellular matrix 
proteins in the glomeruli and tubulointerstitium [5–9].
Protein kinase C-β has been shown to play an im-
portant role in DN in in vivo models. PKC-β1 is an Akt 
S473 kinase, and TGF-β1 transcriptional upregulation 
requires epidermal growth factor receptor (EGFR)/PKC-
β1/Akt signaling. Both PKC-β inhibition and PKC-β 
deletion suppress TGF-β1 upregulation and matrix expan-
sion in diabetic glomeruli or kidneys. New therapeutic 
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approaches to DN may result from targeting components 
of this pathway, particularly the initial EGFR transactiva-
tion [10]. Cell culture studies in podocytes have proven 
that hyperglycemia can activate the RAAS, resulting in 
podocyte apoptosis, which is a hallmark of DN [11–13].
Recent evidence indicates that, in addition to hyper-
glycemia, altered insulin signaling plays an important 
role in podocyte malfunction and in microalbuminuria 
[14,15]. Cell culture studies showed that peroxisome 
proliferator-activated receptor gamma (PPAR-γ) activa-
tion can block the effects of glucose and the RAAS in 
inducing podocyte apoptosis. Similar results are ob-
tained in in vivo models of renal disease associated with 
both DM1 and DM2, where PPAR-γ agonists have been 
shown to be beneficial in preventing DN [13–16].
It has been suggested that osteopontin and macro-
phage accumulation play a role in the tubulointerstitial 
injury of DN, and that inhibition of osteopontin expres-
sion may be one of the mechanisms by which inhibition 
of the β isoform of PKC confers a renoprotective effect. 
There is also increasing evidence that epigenetic mech-
anisms play a role in DN. Epigenetic alterations result 
in regulation of genes that are implicated in regulating 
the metabolism of diabetic complications, including 
AGEs and NF-κB [17–19]. The epigenetic mechanisms 
that constitute a metabolic memory response to episodes 
of transient hyperglycemia are therefore becoming 
major targets for the treatment and prevention of diabetic 
complications including DN.
TREATMENT OPTIONS
Based on its pathogenesis, the initial treatment of DN 
should be strict control of hyperglycemia, hypertension, 
dyslipidemia, proteinuria, and obesity and cessation 
of smoking. The beneficial role of thiazolidinediones 
(TZDs), 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase inhibitors, angiotensin-converting enzyme 
inhibitors (ACEIs), and angiotensin receptor blockers 
(ARBs) in DN is already established. Over the past few 
years our understanding of the complexity of the patho-
genesis of DN has grown as new mechanisms, compo-
nents, and regulatory steps have been identified. Also, 
the potential of targeted therapies has been explored, 
resulting in many novel drugs for the treatment and 
prevention of DN.
NOVEL MOLECULES
Direct renin inhibitor: aliskiren
The central role of the RAAS in the pathogenesis of DN 
is widely accepted based largely on the attenuation of 
DN by ACEIs and ARBs. Because of insufficient sup-
pression of the intrarenal RAAS, however, these agents 
cannot stop disease progression. Theoretically, agents 
that more effectively suppress the RAAS should provide 
improved renal protection against DN. Direct renin in-
hibitors, which act at the point of activation of the RAAS 
cascade, are such agents.
Aliskiren is an orally active, nonpeptide renin inhibi-
tor that is highly specific for renin. It acts by binding to 
the active site of renin, thereby inhibiting catalytic activity. 
As renin acts at the rate-limiting step in the RAAS cas-
cade, blockade of renin with aliskiren may inhibit the 
RAAS and reduce the feedback effects more completely 
than do ACEIs or ARBs. In addition, the blockade of renin 
may reduce activity at the (pro)renin receptor [(P)RR]. 
Therefore, aliskiren may provide superior renoprotection.
Azizi et al showed that in healthy human volunteers 
maintained on a high sodium diet a single 300 mg dose 
of aliskiren caused a reduction in PRA and angiotensin 
I and II levels within 1 hour of administration. In contrast, 
the ARB valsartan increased each of these parameters 
[20]. In streptozocin-induced diabetes mellitus in trans-
genic Ren(2) rats, a model of advanced DN in humans, 
aliskiren reduced albuminuria and glomerulosclerosis 
to an extent similar to that produced by the ACEI perin-
dopril. This effect was seen despite the fact that aliski-
ren did not lower blood pressure as much as perindopril. 
The reduction in tubulointerstitial fibrosis was signifi-
cantly greater in aliskiren-treated diabetic rats than in 
the perindopril-treated animals [21].
The Aliskiren in the Evaluation of Proteinuria in 
Diabetes (AVOID) trial demonstrated that adding aliski-
ren at a dosage of 300 mg/day to the highest approved 
dosage of losartan and optimal antihypertensive therapy 
reduces albuminuria over 6 months among patients with 
DM2, hypertension, and albuminuria. The study con-
cluded that aliskiren had a renoprotective effect that was 
independent of its blood pressure-lowering effect in 
patients with DM2 who were receiving the maximum 
recommended renoprotective treatment and optimal 
antihypertensive therapy [22].
Aliskiren may be antifibrotic because of its nonmu-
tually exclusive (P)RR-mediated actions: 1) suppression 
of (P)RR gene expression, possibly resulting in fewer 
receptors and damping intracellular fibrotic pathways 
induced by (pro)renin; 2) preventing activation of pro-
renin in renal tissue; and 3) negating the gain in catalytic 
activity of receptor-bound renin [23].
The results of these animal and human studies are 
highly encouraging. The results of a large outcome trial 
in diabetic nephropathy, ALTITUDE (Aliskiren Trial 
in Type 2 Diabetes Using Cardiorenal Endpoints), are 
awaited. The primary objective of the ALTITUDE trial 
is to determine whether aliskiren 300 mg once daily re-
duces cardiovascular and renal morbidity and mortality 
compared with placebo when added to conventional treat-
ment (including ACEIs or ARBs). ALTITUDE is an in-
ternational, randomized, double-blind, placebo-controlled, 
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parallel group study that seeks to determine whether dual 
RAAS blockade with the direct renin inhibitor aliskiren 
in combination with an ACEI or ARB can reduce major 
morbidity and mortality in a broad range of high-risk 
patients with DM2 [24,25].
Protein kinase C inhibitor: ruboxistaurin
Ruboxistaurin, an orally active selective inhibitor of the 
β-isoform of PKC, reduces the actions of vascular en-
dothelial growth factor (VEGF) and attenuates the 
progression of diabetic retinopathy. Animal studies have 
shown it to normalize glomerular hyperfiltration and 
reduce TGF-β levels and proteinuria. Excess matrix, 
hypertrophy, and apoptosis are features of DN, and 
ruboxistaurin has been shown to attenuate histological 
injury, functional decline, and expression of the profi-
brotic and proapoptotic growth factor TGF-β [26,27].
Kelly et al showed that both cell loss and VEGF 
overexpression were attenuated by administration of 
either perindopril or ruboxistaurin as single-agent treat-
ment. A combination of the two provided additional, in-
cremental improvement, reducing these manifestations 
of injury to levels seen in nondiabetic, normotensive, 
nontransgenic animals [28]. Ruboxistaurin has also been 
found to reduce osteopontin expression and consequent 
macrophage infiltration in diabetic rats [29]. A random-
ized study showed that patients with DN treated with 
32 mg of ruboxistaurin daily had a 24% greater reduction 
in albuminuria than those given a placebo, and they had 
a stable estimated glomerular filtration rate as well [30].
m-TOR inhibitor: rapamycin (sirolimus)
A serine/threonine kinase, mTOR plays a pivotal role 
in mediating cell size, mass, proliferation, and survival. 
mTOR has also emerged as an important modulator of 
several forms of renal disease [31]. Studies have shown 
that the mTOR pathway is highly activated in progres-
sive renal disorders including DN. Activation of mTOR 
signaling causes renal hypertrophy at an early stage of 
diabetes [32].
Diabetic db/db mice, which lack leptin receptor sig-
naling, have been used as a model of ESRD associated 
with DN. It was demonstrated that p70S6-kinase was 
highly activated in mesangial cells in diabetic obese db/
db mice. Furthermore, systemic administration of rapa-
mycin, a systemic and potent inhibitor of mTOR, markedly 
ameliorated pathological changes and renal dysfunction. 
Rapamycin treatment also significantly reduced fat 
deposits and attenuated hyperinsulinemia, with few side 
effects. These results indicate that mTOR activation plays 
a pivotal role in the development of ESRD, and that ra-
pamycin could be an effective therapeutic agent for DN 
[33]. Yang et al concluded that rapamycin treatment can 
prevent the early renal structural changes of diabetes in 
experimental rats, and thus halt the early steps in the 
development of DN [34].
In another study in rats, sirolimus ameliorated renal 
inflammation, glomerular hypertrophy, and podocyte loss, 
as indicated by morphometric and immunohistological 
analyses. Sirolimus lowered the expression and activity 
of glomerular TGF-β and VEGF, which are considered 
central cytokines in the pathogenesis of DN. Based on its 
anti-inflammatory, antifibrotic, and podocyte-protective 
effects, sirolimus seems to be a superior treatment for 
preventing or ameliorating DN in the rat [35].
Pentoxifylline
Metabolic and hemodynamic components are directly 
involved in the pathogenesis of DN, although there are 
convincing data indicating that inflammation participates 
in the diabetic complications as well. Renal expression 
of proinflammatory cytokines, such as tumor necrosis 
factor-α (TNF-α), interleukin-1 (IL-1), and IL-6, is in-
creased in DN and is significantly associated with urinary 
albumin excretion. Pentoxifylline administration has pre-
vented this enhanced expression, leading to a decrease 
in urinary cytokine excretion and a reduction in albumin-
uria. These findings provide a novel insight into the patho-
genic mechanisms of DN, supporting the hypothesis that 
inflammatory mechanisms play a role in the renal injury 
secondary to diabetes mellitus [36]. A meta-analysis by 
McCormick et al concluded that pentoxifylline may 
decrease proteinuria in patients with DN [37].
A prospective, randomized, double-blind, placebo-
controlled study evaluated the effect of pentoxifylline 
(1200 mg daily for 12 months) in 34 patients with es-
tablished DN. The evaluated parameters were inflam-
mation, proinflammatory cytokines, and urinary albumin 
excretion. Pentoxifylline treatment had a renoprotective 
effect determined by a significant reduction in urinary 
albumin excretion in both incipient and established DN 
patients. This effect was attributed to a reduction in serum 
C-reactive protein, IL-6, TNF-α, and leptin levels. Thus, 
pentoxifylline treatment caused regression and prevented 
the progression of renal damage [38].
The Pentoxifylline for Renoprotection in Diabetic 
Nephropathy (PREDIAN) study, an investigator-initiated, 
single-center, prospective, randomized, controlled, clini-
cal trial funded by the Spanish Ministry of Science and 
Innovation is underway. It was initiated to provide evi-
dence regarding the renoprotective benefit of pentoxifyl-
line in patients with DN, in addition to interventions of 
proven efficacy (RAS blockade) [39].
Advanced glycation end-products inhibitor
The formation of advanced glycation end-products 
(AGEs) is closely linked to glycoxidative biology. By 
investigating the role of AGEs and their receptors (re-
ceptors for AGEs, or RAGE) in the onset and progression 
of DN, future treatment strategies targeting the AGE-
RAGE system have designed: 1) AGE formation inhibi-
tor (ARBs, R-147176, aminoguanidine, benfotiamine, 
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pyridoxamine); 2) AGE cross-link breaker (alagebrium); 
3) RAGE antagonist (PPAR-γ antagonists); 4) AGE 
binder (Kremezin); 5) hypoxia-inducible factor (HIF) 
activator [40].
ARB derivative: R-147176
A novel ARB derivative, R-147176, inhibits oxidative 
stress and AGEs, but has minimal affinity for the angio-
tensin II type 1 receptor (AT1R), and thus little antihy-
pertensive effect. The inhibition of AGEs formation, 
AT1R affinity, and the pharmacokinetic characteristics 
of newly synthesized ARB derivatives were assayed. 
R-147176 was eventually selected, as it strongly inhib-
ited advanced glycation, but was 6,700 times less effec-
tive than olmesartan in regard to AT1R binding. Despite 
a minimal effect on blood pressure, it showed significant 
renoprotection in spontaneously hypertensive/NIH-
corpulent (SHR/NDmcr-cp) rats, as well as in Zucker dia-
betic fatty rats. The renal benefits of ARB thus depend 
on inhibition of AGEs and oxidative stress by their chem-
ical structure. This has opened a new avenue for treating 
normotensive or hypotensive patients with cardiovascu-
lar diseases, including kidney disease [41].
Pyridoxamine
Pyridoxamine is one of three natural forms of vitamin 
B6 and is an active inhibitor of AGEs. Investigation of 
the pyridoxamine mechanism of action demonstrated 
that pyridoxamine inhibits post-Amadori steps of the 
Maillard reaction by sequestering catalytic metal ions 
and blocking oxidative degradation of the Amadori 
intermediate. Pyridoxamine also has the capacity to 
scavenge toxic car bonyl products of sugar and lipid 
degradation, and to inhibit the ROS [42].
In a study by Murakoshi et al pyridoxamine amelio-
rated lipid peroxidation and insulin resistance in KK-
A(y)/Ta mice. This pleiotropic effect of pyridoxamine 
was related to CD36 expression in the kidney and adi-
pose tissue [43]. Pyridoxamine was found to exert 
renoprotective effects and decrease renal pentosidine 
accumulation in experimental chronic allograft nephrop-
athy (CAN), suggesting a detrimental role for renal AGE 
accumulation in the pathogenesis of renal damage in this 
nondiabetic model. These results indicate that inhibition 
of AGE formation might be a useful therapeutic adjunct 
to attenuate CAN [44].
The safety and efficacy of pyridoxamine was studied 
in a Phase II trial (PYR-206). A total of 128 patients 
with DN received either 50 mg of pyridoxamine or pla-
cebo. In another trial (PYR-205/207), 84 patients with 
DM1 and DM2 were recruited. Patients were random-
ized to 250 mg pyridoxamine treatment or placebo. The 
results of these two trials were merged and published. 
Although there was no change in urine albumin excretion, 
the pyridoxamine group had a 48% reduction in serum 
creatinine and reduced TGF-β [45].
Benfotiamine
Benfotiamine (S-benzoylthiamine-O-monophosphate) is 
a synthetic S-acyl derivative of thiamine. Transketolase 
is an enzyme that directs the precursors of AGEs to a pen-
tose phosphate pathway. Benfotiamine administration 
increases the levels of intracellular thiamine diphosphate, 
a cofactor necessary for the activation transketolase, re-
sulting in a reduced level of AGEs in tissues [46]. A study 
by Stirban et al confirmed micro- and macrovascular 
endothelial dysfunction accompanied by increased oxi-
dative stress following a real-life, heat-processed, AGE-
rich meal in individuals with DM2. The authors suggested 
benfotiamine as a potential treatment [47].
Recent advances in understanding the biology of 
endothelial progenitor cells (EPCs) have highlighted 
their involvement in diabetes complications. Results of 
a study by Marchetti et al indicated that hyperglycemia 
impairs EPC differentiation, and that the process can be 
restored by benfotiamine administration via modulation 
of Akt/ FoxO1 activity [48]. In contrast, in a double-blind, 
randomized, placebo-controlled clinical trial on benfo-
tiamine treatment in patients with DN, high-dose benfo-
tiamine treatment for 12 weeks, in addition to ACEIs or 
ARBs, did not reduce urinary albumin excretion or KIM-1 
(kidney injury molecule-1) excretion, despite improved 
thiamine status [49].
Alagebrium (ALT-711)
Alagebrium (4,5-dimethylthiazolium), formerly known 
as ALT-711, is a novel cross-links breaker in AGEs. It 
has been studied in various models of diabetic compli-
cations, and has been shown to attenuate diabetic renal 
disease, cardiac dysfunction, and atherosclerosis. In ad-
dition to the ability of alagebrium to reduce tissue levels 
of AGEs, the drug appears to inhibit activation of certain 
PKC isoforms [50].
Methylglyoxal (MG), a highly reactive dicarbonyl 
compound, is a normal product of glucose, fatty acid, 
and protein metabolism. The clinical significance of MG 
lies in the fact that it reacts with and modifies certain 
proteins to form AGEs, leading to the vascular compli-
cations of diabetes. Dhar et al showed that alagebrium 
pretreatment attenuated these effects of MG. In an in vitro 
assay, alagebrium reduced the amount of detectable MG. 
An acute in vivo effect of alagebrium against MG was 
possibly due to scavenging [51]. Based on their animal 
study, Peppa et al concluded that alagebrium may pre-
vent, delay, and/or reverse established DN in db/db mice, 
by reducing the systemic AGE pools and facilitating 
urinary excretion of AGES [52].
Kremezin (AST-120)
Oral adsorbent Kremezin reduces uremic toxins (e.g. in-
doxyl sulfate) and retards the progression of chronic kidney 
disease (CKD). Kremezin binds to carboxymethyl lysine 
(CML) in vitro, one of the well-characterized digested 
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food-derived AGEs. Administration of Kremezin decreases 
serum AGE levels in nondiabetic patients in chronic renal 
failure (CRF). These findings suggest that digested food-
derived AGEs such as CML may be a novel molecular 
target for oral adsorbent Kremezin, and that Kremezin 
could exert beneficial effects on CRF patients by adsorbing 
diet-derived AGEs and subsequently decreasing serum 
AGE levels [53]. Kremezin reduces the gene expression 
of TGF-β1, tissue inhibitor of metalloproteinase (TIMP)-1, 
and pro-α1(I) collagen in the kidneys. It delays the pro-
gression of CRF by alleviating the overload of indoxyl 
sulfate on remnant proximal tubular epithelial cells [54].
Ueda et al found that Kremezin treatment signifi-
cantly reduced mRNA levels of RAGEs, monocyte che-
moattractant protein-1, and vascular adhesion molecule-1 
in cultured human umbilical vein endothelial cells com-
pared with their baseline levels. This study suggested 
that atheroprotective properties of Kremezin can be 
ascribed, at least in part, to its AGE-lowering ability via 
absorption of CML [55].
Plasminogen activator inhibitor-1 inhibitors
Plasminogen activator inhibitor-1 (PAI-1) can regulate 
TGF-β expression by binding to the urokinase plasmino-
gen activator receptor and activating the extracellular-
regulated signal kinase/mitogen-activated protein kinase 
(ERK/MAPK) pathway. Therefore, PAI-1 contributes 
to DN by regulating TGF-β and renal extracellular 
matrix production. Thus, it may be a therapeutic target 
in DN [56].
Several experimental and clinical studies support the 
role for PAI-1 in the renal fibrogenic process that occurs 
in chronic glomerulonephritis, DN, focal segmental 
glomerulosclerosis, and other fibrotic renal diseases. 
Inhibition of PAI-I activity or of PAI-I synthesis by 
specific antibodies, peptidic antagonists, antisense oligo-
nucleotides, or decoy oligonucleotides has been obtained 
in vitro, but needs to be evaluated in vivo regarding the 
prevention or treatment of renal fibrosis [57].
Disruption of the PAI-I gene protects mice against DN. 
Some novel, orally active, small molecule substances—
TM-5001, TM-5007, TM-5275—were identified [58,59]. 
In vitro, they specifically inhibited PAI-I activity and 
formation of a PAI-I–tissue plasminogen activator (t-PA) 
complex, and they enhanced fibrinolysis. Given to rats 
with Thy-I nephritis, they reduced proteinuria and me-
sangial expansion, a benefit similar to that observed in the 
same model whose PAI-I molecule had been mutated [60]. 
Clinical benefits of PAI-I inhibitors in DN remain to be 
demonstrated. If confirmed, this molecule might expand 
our therapeutic armamentarium to prevent DN [61].
Low-molecular-weight glycosaminoglycan 
polysaccharides: sulodexide
A primary alteration in DN consists of decreasing the 
concentration of glycosaminoglycans (GAGs) in the 
glomerular extracellular matrix. This evidence has 
prompted interest in using exogenous GAGs, specifi-
cally sulodexide, in the treatment of DN [62].
Sulodexide is a commercially available compound 
consisting of heparin sulfate (80%) and dermatan sulfate 
(20%). Sulodexide is degraded in the digestive tract into 
GlcNAc building blocks, leading to an increase in the 
precursors available for GAG synthesis [63].
The Di.N.A.S. study was a randomized, double-blind, 
placebo-controlled, multicenter, dose range-finding trial 
to evaluate the extent and duration of the hypoalbumin-
uric effect of oral sulodexide in diabetic patients. The 
study concluded that a 4-month course of high doses of 
sulodexide significantly and dose-dependently alleviated 
albuminuria in DM1 and DM2 patients and micro- or 
macroalbuminuric patients with or without concomitant 
ACE inhibition [64]. In another trial, sulodexide micro-
albuminuria (SUN-Micro-Trial) given to 1000 patients 
with diabetes and persisting microalbuminuria on maxi-
mum RAAS blockade failed to show a reduction in urine 
albumin. Further studies are needed on this molecule 
before its utility for DN can be determined [65].
Pirfenidone
Pirfenidone (PFD) [5-methyl-1-phenyl-2-(IH)-pyridone] 
is a low-molecular-weight synthetic molecule that exerts 
dramatic antifibrotic properties in cell culture and various 
animal models of fibrosis [66,67]. In cell culture studies 
of mouse mesangial cells, PFD decreased TGF-β pro-
moter activity, reduced TGF-β protein secretion, and 
inhibited TGF-β-induced Smad2 phosphorylation, 3TP-
lux promoter activity, and generation of ROS. In the db/
db mouse, PFD promoted resolution of the mesangial 
matrix when administered after the onset of nephropathy. 
For identification of novel pathways of PFD relevant to 
DN, proteomic studies of the whole kidneys followed by 
bioinformatic analyses revealed RNA processing as a 
novel mechanism of PFD action. In support of PFD play-
ing a role in mRNA translation, PFD was found to regu-
late the activity of eukaryotic initiation factor (eIF4E), 
a key mRNA cap structure-binding protein, in mesangial 
cells in culture [68].
Endothelin-A receptor antagonist: avosentan
The endothelin system regulates a number of renal 
functions, and can induce proteinuria by various mech-
anisms. Plasma and urinary endothelin-1 (ET-1) levels 
are elevated in patients with diabetes, and correlate with 
reduced renal function, increased blood pressure, albu-
minuria, and the severity and duration of diabetes.
Avosentan is a nonpeptidergic, once-daily, orally 
available endothelin-A (ETA) antagonist that is currently 
in clinical development for the treatment of DN. Endo-
thelin antagonists have shown anti-inflammatory, anti-
fibrotic, and antiproteinuric effects in experimental 
studies.
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ASCEND was a multicenter, placebo-controlled trial 
that aimed to investigate the effects of the ETA receptor 
antagonist avosentan in patients with DN. In this study, 
25 mg and 50 mg of avosentan daily substantially re-
duced the albumin/creatinine ratio compared with that 
induced by placebo. They found that avosentan reduced 
albuminuria when added to standard treatment in people 
with DM2 and overt nephropathy, but it induced sig-
nificant fluid overload and congestive heart failure as well 
[69,70]. Wenzel et al conducted a randomized, placebo-
controlled, double-blind, parallel-design, dosage-range 
study on the effect of the ETA antagonist avosentan on 
the urinary albumin excretion rate (UAER) in 286 pa-
tients with DN. The study revealed that avosentin given 
in addition to standard ACEI/ARB treatment decreases 
UAER in patients with DN [71].
CONCLUSION
During the past half-century, a global pandemic of kid-
ney failure attributed to diabetes mellitus has provoked 
continuously changing treatment strategies based on the 
belief that micro- and macrovascular complications of 
diabetes are preventable. In diabetic patients with overt 
nephropathy, multiple pharmacological interventions have 
represented a promising pathway to preventing progres-
sion to ESRD. This review addressed some of the more 
promising therapeutic agents for delaying the progres-
sion of diabetic kidney disease. The diversity of therapies 
currently in development reflects the pathogenic com-
plexity of diabetic nephropathy. These novel agents, target-
ing several culprit areas, should provide additional, much 
needed benefits, but translation of these experimental 
achievements to the clinical world is still limited or lack-
ing. We look forward to witnessing successful manage-
ment of diabetic nephropathy in the near future.
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